English
Anti-CD20 CAR-T Cells
Anti-CD20 CAR-T Cells
Artikelnummer
BPS78611
Verpackungseinheit
1 vial
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Use as positive control for anti-CD20 CAR-T cellsScreen modulators of anti-CD20 CAR-T cytotoxicityDesign and optimize co-culture cytotoxicity assays
Background: CD20 (also known as MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an "Essential Medicine". Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin's lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.
Description: The anti-CD20 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD20 CAR Lentivirus (CD20 ScFv-CD8-4-1BB-CD3ζ; BPS Bioscience #78606). These ready-to use CAR-T cells express an anti-CD20 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.
Mycoplasma Testing: The cells have been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of CryoStor® CS10 (Stemcell Technologies)
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles.Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.
Biosafety Level: BSL-1
Applications: Use as positive control for anti-CD20 CAR-T cellsScreen modulators of anti-CD20 CAR-T cytotoxicityDesign and optimize co-culture cytotoxicity assays
Background: CD20 (also known as MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an "Essential Medicine". Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin's lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.
Description: The anti-CD20 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD20 CAR Lentivirus (CD20 ScFv-CD8-4-1BB-CD3ζ; BPS Bioscience #78606). These ready-to use CAR-T cells express an anti-CD20 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.
Mycoplasma Testing: The cells have been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of CryoStor® CS10 (Stemcell Technologies)
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles.Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.
Biosafety Level: BSL-1
| Artikelnummer | BPS78611 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 78611 |
| Verpackungseinheit | 1 vial |
| Mengeneinheit | STK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
